. 2018 Apr 13;18:418. doi: 10.1186/s12885-018-4333-6

Table 1.

Baseline clinicopathological characteristics of studied endometrial cancers cohorts

	Entire Cohort N = 342	Group A N = 215	Group B N = 127	p ^*
Histology	Endometrioid and non-endometrioid endometrial cancers	Low- and moderate- grade endometroid endometrial cancer	Non-endometrioid and high-grade endometroid endometrial cancer	p ^*
Age [years] (mean ± SD^**)	67.424 ± 8.399	65.167 ± 6.661	71.244 ± 9.599	< 0.0001^#
BMI [kg/m²] (mean ± SD^**)	24.945 ± 3.195	25.774 ± 3.488	23.542 ± 1.952	< 0.0001^#
Stage^***				< 0.0001^#
1	174 (50.88%)	133 (61.86%)	41 (32.28%)
2	93 (27.19%)	45 (20.93%)	48 (37.80%)
3	71 (20.76%)	35 (16.28%)	36 (28.35%)
4	4 (1.17%)	2 (0.93%)	2 (1.57%)
Grade				< 0.0001^#
1	90 (26.31%)	90 (41.86%)	0 (0.00%)
2	132 (38.60%)	125 (58.14%)	7 (5.51%)
3	120 (35.09%)	0 (0.00%)	120 (94.49%)
MI^*** ≥ 50%	258 (75.44%)	148 (68.84%)	110 (86.61%)	0.0002^#
+LN^&	40 (11.70%)	15 (7.44%)	25 (19.68%)	0.0004^#
+LVSI^&&	94 (27.49%)	42 (19.53%)	52 (40.94%)	< 0.0001^#
+MELF^&&&	18 (5.26%)	18 (8.37%)	0 (0.00%)	< 0.0001^#
Adjuvant therapy				< 0.0001^#
VBTH^A	175 (51.17%)	107 (49.77%)	68 (53.54%)
ERTH^B	26 (7.61%)	0 (0.00%)	26 (20.47%)
CHT^C	33 9.65%)	32 (14.88%)	1 (0.79%)
HTH^D	2 (0.58%)	2 (0.92%)	0 (0.00%)
VBTH^A + ERTH^B	10 (2.92%	0 (0.00%)	10 (7.87%)
ERTH^B + CHT^C	25 (7.31%)	3 (1.39%)	22 (17,33%)
none	71 (20.76%)	71 (33.04%)	0 (0.00%)
Recurrence	46 (13.45%)	20 (9.30%)	26 (20.47%)	0.0034^#

* Comparison between Groups A and B; *SD – standard deviation; *** stage of disease according to the 2010 (FIGO) classification; ***MI - myometrial invasion; ^&LN - lymph node involvement; ^&&LVSI - lymphovascular space invasion; ^#statistically significant p-value; ^AVBTH – vaginal brachytherapy; ^BERTH – external radiotherapy; ^CCHT – chemotherapy; ^DHTH – hormonal therapy